September 15th 2025
Viridian plans to submit a Biologics License Application (BLA) for VRDN-003 by year-end of 2026.
ASCRS 2023: Cenegermin 0.002%: effective for corneal nerve regeneration in neurotrophic keratitis
May 5th 2023In a presentation at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Ana Balbuena-Pareja, MSc, explained how cenegermin-bkbj ophthalmic solution 0.002% (Oxervate, Dompé) had a positive effect on corneal nerve regeneration and sensation in patients with neurotrophic keratitis.
Read More
IKA Keratoconus Symposium 2023: In-person white paper development, live patient Q&A
April 22nd 2023President and CEO of the International Keratoconus Academy Andrew Morgenstern, OD, FAAO, FNAP, shares some snippets about the live white paper development session and the patient Q&A happening at the inaugural IKA Keratoconus Symposium.
Read More
Ophthalmology helping Major Leaguer stay on the diamond
April 7th 2023Ophthalmologists can learn the latest techniques to help patients like Tommy Pham from the New York Mets during the first annual IKA Keratoconus Symposium: Front to Back and Everything In Between, taking place April 22-23 in Scottsdale, Arizona.
Read More
Trends in corneal treatment include cutting-edge advancements
March 15th 2023Kamran M. Riaz, MD, a clinical associate professor and director of Medical Student Research at the Dean A. McGee Institute at the University of Oklahoma, recently discussed with Ophthalmology Times some of the latest trends in cornea treatment.
Read More
BRIM Biotechnology receives FDA orphan drug designation for treatment of neurotrophic keratitis
December 8th 2022Receiving FDA orphan drug designation allows the company to proceed with plans to advance the development of BRM424, a novel, first-in-class, potential treatment for neurotrophic keratitis.
Read More